Quantifying the Value of Stroke Disability Outcomes: WHO Global Burden of Disease Project Disability Weights for Each Level of the Modified Rankin Scale

Background and Purpose— The modified Rankin Scale (mRS) categorizes poststroke disability among 7 broad, ordinal grades, but the interval distances between these levels are spaced along the disability spectrum have not been previously investigated. Methods— We used the person trade-off procedure developed by the World Health Organization Global Burden of Disease Project (WHO-GBDP) to generate disability weights (DWs) ranging from 0 (normal) to 1 (dead) for each of 7 mRS grades. The ratings of an international, 9-member panel of stroke experts were combined by a modified Delphi process. Results— DWs (95% CI) were 0 for mRS 0, 0.046 (0.004 to 0.088) for mRS 1, 0.212 (0.175 to 0.250) for mRS 2, 0.331 (0.292 to 0.371) for mRS 3, 0.652 (0.625 to 0.678) for mRS 4, 0.944 (0.873 to 1.015) for mRS 5, and 1.0 for mRS 6. DWs of adjacent mRS levels were significantly different (P<0.001 for all). Coefficients of variation showed a high degree of consensus for DWs among panel members. DWs placed each of the 5 intermediate mRS states in different disability class levels of the WHO-GBDP anchor conditions and identified natural clusters to use when reducing the mRS to fewer categories. Conclusions— Formal DW assignment confirms that the mRS is an ordered but unequally spaced scale. The availability of DWs for each mRS level now permits direct comparison of each poststroke outcome state with the outcomes of hundreds of other diseases in the WHO-GBDP and the expression of stroke burden in different populations by using the uniform metric of disability-adjusted life-years lost.

[1]  K. Yu,et al.  Impact of neurological and medical complications on 3‐month outcomes in acute ischaemic stroke , 2008, European journal of neurology.

[2]  Peter P. Wakker,et al.  The Utility of Health States After Stroke: A Systematic Review of the Literature , 2001, Stroke.

[3]  J. Koziol NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.

[4]  S. Gabriel,et al.  Systematic Review of the Literature , 2021, Adherence to Antiretroviral Therapy among Perinatal Women in Guyana.

[5]  Gouke J. Bonsel,et al.  Disability Weights for Diseases: A Modified Protocol and Results for a Western European Region , 2000 .

[6]  Qi-dong Yang,et al.  Incidence and Trends of Stroke and Its Subtypes in China: Results From Three Large Cities , 2006, Stroke.

[7]  J. Lee,et al.  Patient Preferences for Stroke Outcomes , 1994, Stroke.

[8]  M. Benatar,et al.  Outcome Analysis in Clinical Trial Design for Acute Stroke: Physicians’ Attitudes and Choices , 2008, Cerebrovascular Diseases.

[9]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[10]  J. Richardson,et al.  The importance of Perspective in the Measurement of Quality-adjusted Life Years , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  Christian Weimar,et al.  Assessment of Functioning and Disability After Ischemic Stroke , 2002, Stroke.

[12]  Michael D Hill,et al.  Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. , 2004, The New England journal of medicine.

[13]  Shotai Kobayashi,et al.  Analysis of subarachnoid hemorrhage according to the Japanese Standard Stroke Registry Study--incidence, outcome, and comparison with the International Subarachnoid Aneurysm Trial. , 2004, Neurologia medico-chirurgica.

[14]  J. Broderick,et al.  The Unchanging Incidence and Case-Fatality of Stroke in the 1990s: A Population-Based Study , 2006, Stroke.

[15]  P. Rothwell,et al.  Outcome after spontaneous and arteriovenous malformation-related intracerebral haemorrhage: population-based studies. , 2008, Brain : a journal of neurology.

[16]  D K Owens,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.

[17]  Wayne K. Talley,et al.  Stability and agreement criteria for the termination of Delphi studies , 1979 .

[18]  E. Nord,et al.  Methods for quality adjustment of life years. , 1992, Social science & medicine.

[19]  H. Diener,et al.  Association Between Disability Measures and Healthcare Costs After Initial Treatment for Acute Stroke , 2007, Stroke.

[20]  E. Nord The Person-trade-off Approach to Valuing Health Care Programs , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. , 2008, The New England journal of medicine.

[22]  Nirds,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group , 1995 .

[23]  Pao-Yang Chen International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion , 2007 .

[24]  D. Hunter,et al.  Qualitative Research: Consensus methods for medical and health services research , 1995 .

[25]  S. Hallan,et al.  Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes , 1999, Journal of internal medicine.

[26]  P. Sandercock,et al.  International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion , 2005, The Lancet.

[27]  B. Norrving,et al.  Functional Outcome 3 Months after Stroke Predicts Long-Term Survival , 2008, Cerebrovascular Diseases.

[28]  J Lipscomb,et al.  Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. , 1999, Journal of clinical epidemiology.

[29]  G. Andrews,et al.  Burden of disease , 1998, British Journal of Psychiatry.